Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Faber, Mette Tuxen ; Duun-Henriksen, Anne Katrine ; Dehlendorff, Christian ; Tatla, Manrinder Kaur ; Munk, Christian ; Kjaer, Susanne K. / Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy. In: Vaccine. 2019 ; Vol. 37, No. 2. pp. 265-271.

Bibtex

@article{167d40017022454dac6acfb1d39fea1c,
title = "Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy",
abstract = "BACKGROUND: Few studies have studied the association between unintended human papillomavirus (HPV) vaccination and adverse pregnancy outcomes. This study set out to determine the association between HPV vaccination during pregnancy and subsequent risk of spontaneous abortion, stillbirth, and one-year infant mortality.METHODS: Population-based study including all pregnancies in Denmark (October 2006-December 2014) among women born 1975-1992. From nationwide health registries using the personal identification numbers, we obtained information on HPV vaccination, pregnancy outcomes, and infant mortality. The exposure window went from four weeks before conception date until 22 weeks of gestation for the outcome spontaneous abortion, and until birth for stillbirth and infant mortality outcomes. In the analyses of spontaneous abortion, we used time to event models, for stillbirth logistic regression models, and for infant mortality Cox regression was applied.RESULTS: We included 522,705 pregnancies for the outcome spontaneous abortion (7487 exposed to at least one dose during pregnancy); 351,878 births (5262 exposed to at least one dose during pregnancy) for the stillbirth; and 350,739 live births (5245 exposed to at least one dose during pregnancy) for infant mortality. No significantly increased rate of spontaneous abortion among women vaccinated during pregnancy compared with unvaccinated women was found. In addition, we found no association between HPV vaccination during pregnancy and stillbirth (adjusted odds ratio = 0.96 [95% CI: 0.57-1.61]), or infant mortality (adjusted hazard ratio = 0.94 [95% CI: 0.53-1.67]). A secondary analysis showed no association between number of doses and timing of administration (i.e. vaccination before or during pregnancy) and an increased risk of spontaneous abortion.CONCLUSION: We found no increased risk of spontaneous abortion, stillbirth, or infant mortality following unintended HPV vaccination during pregnancy.",
author = "Faber, {Mette Tuxen} and Duun-Henriksen, {Anne Katrine} and Christian Dehlendorff and Tatla, {Manrinder Kaur} and Christian Munk and Kjaer, {Susanne K}",
note = "Copyright {\textcopyright} 2018 Elsevier Ltd. All rights reserved.",
year = "2019",
month = jan,
day = "7",
doi = "10.1016/j.vaccine.2018.11.030",
language = "English",
volume = "37",
pages = "265--271",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Adverse pregnancy outcomes and infant mortality after quadrivalent HPV vaccination during pregnancy

AU - Faber, Mette Tuxen

AU - Duun-Henriksen, Anne Katrine

AU - Dehlendorff, Christian

AU - Tatla, Manrinder Kaur

AU - Munk, Christian

AU - Kjaer, Susanne K

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2019/1/7

Y1 - 2019/1/7

N2 - BACKGROUND: Few studies have studied the association between unintended human papillomavirus (HPV) vaccination and adverse pregnancy outcomes. This study set out to determine the association between HPV vaccination during pregnancy and subsequent risk of spontaneous abortion, stillbirth, and one-year infant mortality.METHODS: Population-based study including all pregnancies in Denmark (October 2006-December 2014) among women born 1975-1992. From nationwide health registries using the personal identification numbers, we obtained information on HPV vaccination, pregnancy outcomes, and infant mortality. The exposure window went from four weeks before conception date until 22 weeks of gestation for the outcome spontaneous abortion, and until birth for stillbirth and infant mortality outcomes. In the analyses of spontaneous abortion, we used time to event models, for stillbirth logistic regression models, and for infant mortality Cox regression was applied.RESULTS: We included 522,705 pregnancies for the outcome spontaneous abortion (7487 exposed to at least one dose during pregnancy); 351,878 births (5262 exposed to at least one dose during pregnancy) for the stillbirth; and 350,739 live births (5245 exposed to at least one dose during pregnancy) for infant mortality. No significantly increased rate of spontaneous abortion among women vaccinated during pregnancy compared with unvaccinated women was found. In addition, we found no association between HPV vaccination during pregnancy and stillbirth (adjusted odds ratio = 0.96 [95% CI: 0.57-1.61]), or infant mortality (adjusted hazard ratio = 0.94 [95% CI: 0.53-1.67]). A secondary analysis showed no association between number of doses and timing of administration (i.e. vaccination before or during pregnancy) and an increased risk of spontaneous abortion.CONCLUSION: We found no increased risk of spontaneous abortion, stillbirth, or infant mortality following unintended HPV vaccination during pregnancy.

AB - BACKGROUND: Few studies have studied the association between unintended human papillomavirus (HPV) vaccination and adverse pregnancy outcomes. This study set out to determine the association between HPV vaccination during pregnancy and subsequent risk of spontaneous abortion, stillbirth, and one-year infant mortality.METHODS: Population-based study including all pregnancies in Denmark (October 2006-December 2014) among women born 1975-1992. From nationwide health registries using the personal identification numbers, we obtained information on HPV vaccination, pregnancy outcomes, and infant mortality. The exposure window went from four weeks before conception date until 22 weeks of gestation for the outcome spontaneous abortion, and until birth for stillbirth and infant mortality outcomes. In the analyses of spontaneous abortion, we used time to event models, for stillbirth logistic regression models, and for infant mortality Cox regression was applied.RESULTS: We included 522,705 pregnancies for the outcome spontaneous abortion (7487 exposed to at least one dose during pregnancy); 351,878 births (5262 exposed to at least one dose during pregnancy) for the stillbirth; and 350,739 live births (5245 exposed to at least one dose during pregnancy) for infant mortality. No significantly increased rate of spontaneous abortion among women vaccinated during pregnancy compared with unvaccinated women was found. In addition, we found no association between HPV vaccination during pregnancy and stillbirth (adjusted odds ratio = 0.96 [95% CI: 0.57-1.61]), or infant mortality (adjusted hazard ratio = 0.94 [95% CI: 0.53-1.67]). A secondary analysis showed no association between number of doses and timing of administration (i.e. vaccination before or during pregnancy) and an increased risk of spontaneous abortion.CONCLUSION: We found no increased risk of spontaneous abortion, stillbirth, or infant mortality following unintended HPV vaccination during pregnancy.

U2 - 10.1016/j.vaccine.2018.11.030

DO - 10.1016/j.vaccine.2018.11.030

M3 - Journal article

C2 - 30503078

VL - 37

SP - 265

EP - 271

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 2

ER -

ID: 56088173